跳至主要内容
临床试验/NCT00486473
NCT00486473已完成3 期

Phase III Multicenter Double-Blind, Randomized, Crossover Study to Compare MultiHance With Magnevist in Contrast-enhanced Magnetic Resonance Imaging (MRI) of the Breast

Bracco Diagnostics, Inc1 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2007年7月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
130
试验地点
1
主要终点
Sensitivity in diagnosing breast lesions compared to histopathology results

研究概览

简要总结

To show if one MRI contrast agent is better than another one in the diagnosis of malignant breast lesions compared to histopathology

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Diagnostic
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Provides written informed consent
  • Age 18 years or older
  • Suspicious or known breast lesion based on results from mammography or ultrasound
  • Planned to undergo histological diagnosis of breast lesion by having a non surgical biopsy or breast surgery within 30 days after the MRI exam

排除标准

  • Body weight > 100 kg
  • Pregnant or lactating
  • Server or end-stage organ failure
  • Moderate to severe renal impairment
  • Undergoing radiotherapy or completed radiotherapy in the last 18 months
  • Chemotherapy within 6 months of the 1st MRI exam

结局指标

主要结局

Sensitivity in diagnosing breast lesions compared to histopathology results

时间窗: up to 6 months

次要结局

  • Sensitivity, specificity, accuracy, PPV and NPV at region, breast and patient levels(up to 6 months)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验